Federal Register of Legislation - Australian Government

Primary content

PB 45 of 2009 Specifications as made
This Specification amends the National Health (Pharmaceutical Benefits - Early Supply) - specification under subsection 84AAA(2) Instrument 2009 (No. PB 30 of 2009) to enable resupply of pharmaceutical items inside 20 days.
Administered by: Health
Registered 28 May 2009
Tabling HistoryDate
Tabled HR01-Jun-2009
Tabled Senate15-Jun-2009
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 45 of 2009

National Health (Pharmaceutical Benefits – Early Supply) Amendment, June 2009 - Specification Under Subsection 84AAA(2)

 

Amendment determination under subsection 84AAA(2) of the National Health Act 1953

 

I, Linda Jackson, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated          22      May 2009

 

 

LINDA JACKSON

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

 

 

 

Amendment determination — Pharmaceutical Benefits-Early Supply

 

 

1          Name of Instrument

 

(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment, June 2009 - specification under subsection 84AAA(2).

 

(2)           This Instrument may also be cited as “No. PB 45 of 2009”.


 

2          Commencement

 

This Instrument commences on 1 June 2009.

 

 

3          Amendment of PB 30 of 2009

 

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, PB 30 of 2009.

 


Schedule 1        Amendments

[1]                                  Schedule 1, item dealing with Efalizumab

omit from the columns in the order indicated:

 

Efalizumab

Injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL

Injection

1

5

 

 

[2]                                  Schedule 1, item dealing with Oestrogens--conjugated with medroxyprogesterone

omit from the columns in the order indicated:

 

Oestrogens--conjugated with medroxyprogesterone

Tablets containing conjugated oestrogens 625 micrograms with medroxyprogesterone acetate 2.5 mg, 28

Oral

1

5

 

Tablets containing conjugated oestrogens 625 micrograms with medroxyprogesterone acetate 5 mg, 28

Oral

1

5

 

 

[3]                                  Schedule 1, item dealing with Pantoprazole

insert in the columns before item dealing with Tablet (enteric coated) 20 mg (as sodium sesquihydrate):

 

 

Sachet containing granules 40 mg (as sodium sesquihydate)

Oral

30

5

 

 

[4]                                  Schedule 1, item dealing with Phenoxybenzamine

insert in the columns after item dealing with Capsule containing phenoxybenzamine hydrochloride 10 mg:

 

 

Capsules containing phenoxybenzamine hydrochloride 10 mg, 100

Oral

1

5

 

 

[5]                                  Schedule 1, after item dealing with Risedronate sodium and calcium carbonate

insert in the columns in the order indicated:

 

Risedronate sodium and calcium carbonate with colecalciferol

Pack containing 4 tablets risedornate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 micrograms

Oral

1

5